• All
  • Important
  • Financial Update
  • Fund Raise
  • Board Meeting
  • Dividend/Bonus
  • JV/Acquisition
  • Investor Meet
  • Insider Trade
  • Pledging
  • Others
    ALPHA TRIBE

    Aurobindo Pharma Limited — Updates, 19-09-2025: General Updates

    19-09-2025 | 10:16 am

    Aurobindo Pharma's subsidiary, CuraTeQ Biologics, successfully completed Phase 3 trials for its denosumab biosimilar, demonstrating comparable efficacy for osteoporosis treatment. This development paves the way for regulatory filings in major markets.

    No comments yet. Be the first to comment!

    All announcements from Aurobindo Pharma Limited